Regional multi-center randomized trial of three vonoprazan-amoxicillin dosing regimens for <i>Helicobacter pylori</i> eradication in Sichuan Province, China
VPZ-AMO dual therapy achieved excellent eradication, safety, and patient compliance. All regimens were similarly effective, whereas the 0.5 g QID dosing strategy offered the most favorable balance of efficacy and tolerability, supporting its use as a first-line option in high-prevalence settings.
Institutions
- Affiliated Hospital of Southwest Medical University (CN)
- Suizhou Central Hospital (CN)
- Fourth People's Hospital of Sichuan Province (CN)
- Deyang Stomatological Hospital (CN)
- The People's Hospital of Guangxi Zhuang Autonomous Region (CN)
- Neijiang Normal University (CN)
- Chengdu Fifth People's Hospital (CN)
- Sichuan Provincial Hospital of Traditional Chinese Medicine (CN)
- The First People's Hospital of Tianmen (CN)
- Qujiang People's Hospital (CN)
- Zigong First People's Hospital (CN)
- Second People’s Hospital of Yibin (CN)
- Ningbo No.6 Hospital (CN)
- Chengdu University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- World Journal of Gastroenterology
- Published
- 2025-12-19
- DOI
- https://doi.org/10.3748/wjg.v31.i47.114377
- Citations
- 1
- Primary Topic
- Helicobacter pylori-related gastroenterology studies
- Type
- article
- Field-Weighted Citation Impact
- 2.01